CD47’s long goodbye
Despite magrolimab’s latest flop, efforts to target CD47 continue.
Gilead doubles down on Arcus
Will a TIGIT refocus see the stars finally align for the partners?
Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Akeso builds on earlier success with bispecifics
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
ASH 2023 – Arcellx still hopes to challenge Carvykti
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.
